Imatinib is a KIT-targeted TKI that is approved for patients with multiple hematologic malignancies, including adult patients with ASM without the KIT D816V mutation or with unknown KIT mutational status (Gleevec package insert. The gene discussed is KIT; the disease is hematologic disorder.